T1	HMM 175 194	Safety and efficacy
T2	HMM 724 753	was time to progression (TtP)
T3	HMM 776 862	evaluated overall response rate (ORR), overall survival (OS), and adverse events (AEs)
T4	HMM 1157 1164	0.009).
T5	HMM 1250 1253	and
T6	HMM 1351 1354	CD.
T7	HMM 1454 1461	40.8%).
T8	HMM 1462 1474	TtP, OS, and
T9	HMM 1550 1645	greater fatigue, hepatotoxicity, neutropenia, and thrombocytopenia but not febrile neutropenia;
T10	HMM 1656 1721	more hand-foot syndrome, gastrointestinal toxicity, and mucositis
T11	HMM 1754 1783	similar efficacy and toxicity
